MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. More Details
+ 1 more risk
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has MGC Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MXC is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: MXC's weekly volatility has increased from 16% to 25% over the past year.
7 Day Return
1 Year Return
Return vs Industry: MXC exceeded the Australian Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: MXC exceeded the Australian Market which returned 37.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is MGC Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StIf You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
4 months ago | Simply Wall StWhat Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
1 year ago | Simply Wall StDo Directors Own MGC Pharmaceuticals Limited (ASX:MXC) Shares?
Is MGC Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MXC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MXC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MXC is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: MXC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MXC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MXC is overvalued based on its PB Ratio (104.1x) compared to the AU Pharmaceuticals industry average (3.3x).
How is MGC Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MGC Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has MGC Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MXC is currently unprofitable.
Growing Profit Margin: MXC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MXC is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare MXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: MXC has a negative Return on Equity (-1239.43%), as it is currently unprofitable.
How is MGC Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MXC's short term assets (A$4.1M) do not cover its short term liabilities (A$7.4M).
Long Term Liabilities: MXC's short term assets (A$4.1M) exceed its long term liabilities (A$3.2M).
Debt to Equity History and Analysis
Debt Level: MXC's debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: MXC's debt to equity ratio has reduced from 15.3% to 7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MXC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MXC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32% each year
What is MGC Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MXC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MXC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MXC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Roby Reuven Zomer is a Co-Founder of MGC Pharmaceuticals Limited. Mr. Zomer has been Managing Director since May 2018 and Chief Executive Officer of MGC Pharmaceuticals Limited (Australia) since Februa...
CEO Compensation Analysis
Compensation vs Market: Roby's total compensation ($USD342.03K) is about average for companies of similar size in the Australian market ($USD287.37K).
Compensation vs Earnings: Roby's compensation has been consistent with company performance over the past year.
Experienced Management: MXC's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: MXC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MXC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.9%.
MGC Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: MGC Pharmaceuticals Limited
- Ticker: MXC
- Exchange: ASX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$139.278m
- Shares outstanding: 2.28b
- Website: https://www.mgcpharma.com.au
- MGC Pharmaceuticals Limited
- 1202 Hay Street
- West Perth
- Western Australia
MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for th...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 08:29|
|End of Day Share Price||2021/05/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.